Nektar Therapeutics Competitors

Nektar Therapeutics (NASDAQ:NKTR) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares Nektar Therapeutics and Johnson & Johnson's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Nektar Therapeutics and Johnson & Johnson's top-line revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Nektar Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Insider & Institutional Ownership

96.4% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 67.4% of Johnson & Johnson shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Nektar Therapeutics and Johnson & Johnson, as provided by MarketBeat.com.

Nektar Therapeutics currently has a consensus price target of $31.8182, suggesting a potential upside of 93.07%. Johnson & Johnson has a consensus price target of $166.0769, suggesting a potential upside of 15.59%. Given Nektar Therapeutics' higher probable upside, research analysts clearly believe Nektar Therapeutics is more favorable than Johnson & Johnson.

Summary

Johnson & Johnson beats Nektar Therapeutics on 9 of the 14 factors compared between the two stocks.

Nektar Therapeutics (NASDAQ:NKTR) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares Nektar Therapeutics and Pfizer's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Nektar Therapeutics and Pfizer's top-line revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Nektar Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.

Insider & Institutional Ownership

96.4% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 69.1% of Pfizer shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Nektar Therapeutics and Pfizer, as provided by MarketBeat.com.

Nektar Therapeutics currently has a consensus price target of $31.8182, suggesting a potential upside of 93.07%. Pfizer has a consensus price target of $40.00, suggesting a potential upside of 9.50%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Nektar Therapeutics is more favorable than Pfizer.

Nektar Therapeutics (NASDAQ:NKTR) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares Nektar Therapeutics and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Nektar Therapeutics and Merck & Co., Inc.'s top-line revenue, earnings per share (EPS) and valuation.

Merck & Co., Inc. has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Nektar Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.

Insider & Institutional Ownership

96.4% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 73.2% of Merck & Co., Inc. shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by company insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Nektar Therapeutics and Merck & Co., Inc., as provided by MarketBeat.com.

Nektar Therapeutics currently has a consensus price target of $31.8182, suggesting a potential upside of 93.07%. Merck & Co., Inc. has a consensus price target of $95.3333, suggesting a potential upside of 19.08%. Given Nektar Therapeutics' higher probable upside, research analysts clearly believe Nektar Therapeutics is more favorable than Merck & Co., Inc..

Summary

Merck & Co., Inc. beats Nektar Therapeutics on 9 of the 14 factors compared between the two stocks.

Nektar Therapeutics (NASDAQ:NKTR) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Insider & Institutional Ownership

96.4% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 64.2% of AbbVie shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Nektar Therapeutics and AbbVie, as provided by MarketBeat.com.

Nektar Therapeutics currently has a consensus price target of $31.8182, suggesting a potential upside of 93.07%. AbbVie has a consensus price target of $111.00, suggesting a potential upside of 6.53%. Given Nektar Therapeutics' higher probable upside, research analysts clearly believe Nektar Therapeutics is more favorable than AbbVie.

Profitability

This table compares Nektar Therapeutics and AbbVie's net margins, return on equity and return on assets.

Volatility and Risk

Nektar Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Valuation and Earnings

This table compares Nektar Therapeutics and AbbVie's top-line revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Nektar Therapeutics on 9 of the 14 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Institutional & Insider Ownership

64.8% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 96.4% of Nektar Therapeutics shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 3.0% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Bristol-Myers Squibb and Nektar Therapeutics, as provided by MarketBeat.

Bristol-Myers Squibb currently has a consensus target price of $74.20, suggesting a potential upside of 18.08%. Nektar Therapeutics has a consensus target price of $31.8182, suggesting a potential upside of 93.07%. Given Nektar Therapeutics' higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Bristol-Myers Squibb.

Profitability

This table compares Bristol-Myers Squibb and Nektar Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Valuation & Earnings

This table compares Bristol-Myers Squibb and Nektar Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Summary

Bristol-Myers Squibb beats Nektar Therapeutics on 8 of the 14 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Institutional & Insider Ownership

76.4% of Eli Lilly and shares are owned by institutional investors. Comparatively, 96.4% of Nektar Therapeutics shares are owned by institutional investors. 0.1% of Eli Lilly and shares are owned by company insiders. Comparatively, 3.0% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Eli Lilly and and Nektar Therapeutics, as provided by MarketBeat.

Eli Lilly and currently has a consensus target price of $168.9286, suggesting a potential upside of 16.70%. Nektar Therapeutics has a consensus target price of $31.8182, suggesting a potential upside of 93.07%. Given Nektar Therapeutics' higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Eli Lilly and.

Profitability

This table compares Eli Lilly and and Nektar Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Eli Lilly and has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Valuation & Earnings

This table compares Eli Lilly and and Nektar Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Eli Lilly and has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Summary

Eli Lilly and beats Nektar Therapeutics on 10 of the 15 factors compared between the two stocks.